Borer, the Cornell doctor who served on the panel, says a drug that increases mortality but lessens the shortness of breath caused by heart failure might have a place.
Simdax, which Abbott had licensed from Finland-based Orion Pharmaceuticals, could potentially help doctors provide relief a million-and-a-half times per year as patients suffer from heart failure that makes them extremely sick and short of breath.